Description
The BioStabilization Systems (BoSS) program aims to transform how live cell-based therapies are stabilized, manufactured, and distributed. The program seeks to develop innovative technologies that preserve cells at ambient temperatures, addressing a foundational bottleneck in the delivery of advanced cell and gene therapies. Proposals are required to address solutions to both Technical Area 1 (BioPrep) and Technical Area 2 (Bioprocessing). The program consists of three phases, with increasingly stringent technological capability requirements and stabilized cell quality metrics. The ideal bioprocessing system will integrate seamlessly with biomanufacturing and fill-finish systems, enabling scalable production of stabilized cell products that meet Good Laboratory Practice (GLP) and GMP standards.
Some key points to consider:
• The program seeks to develop a bioprocessing system that enables scalable production of thermally stable cells.
• Proposals must address solutions to both Technical Area 1 (BioPrep) and Technical Area 2 (Bioprocessing).
• The program consists of three phases, with increasingly stringent technological capability requirements and stabilized cell quality metrics.
• The ideal bioprocessing system will integrate seamlessly with biomanufacturing and fill-finish systems.
• The program aims to establish a new paradigm for biomanufacturing, reducing costs and ensuring that biological medicines are accessible to patients.